Psychoactive plants used in designer drugs as a threat to public health

• Autorzy: Rondzisty A. , Dziekan K. , Kowalska A.

Warianty tytułu

PL

Rośliny psychoaktywne w dopalaczach jako zagrożenie dla zdrowia publicznego

• Języki publikacji: EN

Abstrakty

EN

Based on epidemiologic surveys conducted in 2007–2013, an increase in the consumption of psychoactive substances has been observed. This growth is noticeable in Europe and in Poland. With the ‘designer drugs’ launch on the market, which ingredients were not placed on the list of controlled substances in the Misuse of Drugs Act, a rise in the number and diversity of psychoactive agents and mixtures was noticed, used to achieve a different state of mind. Thus, the threat to the health and lives of people who use them has grown. In this paper, the authors describe the phenomenon of the use of plant psychoactive substances, paying attention to young people who experiment with new narcotics. This article also discusses the mode of action and side effects of plant materials proscribed under the Misuse of Drugs Act in Poland.

PL

Na podstawie badań epidemiologicznych w Polsce i Europie w latach 2007–2013 zaobserwowano wzrost konsumpcji środków psychoaktywnych. Wraz z wprowadzeniem na rynek tzw. dopalaczy, których składniki do 2009 r. nie znajdowały się na liście substancji kontrolowanych przepisami Ustawy o przeciwdziałaniu narkomanii, zwiększyła się liczba i różnorodność stosowanych substancji psychoaktywnych oraz ich mieszanek. Tym samym też wzrosło zagrożenie dla zdrowia i życia osób je zażywających. W niniejszej pracy autorzy omawiają zjawisko zażywania substancji psychoaktywnych pochodzenia roślinnego ze zwróceniem uwagi na jego występowanie wśród młodzieży, chętnie eksperymentującej z nowymi narkotykami. Artykuł również omawia sposób działania oraz działania niepożądane zażywania produktów zawierających surowce roślinne, które zostały zdelegalizowane na mocy ustawy o przeciwdziałaniu narkomanii w Polsce.

Słowa kluczowe

EN

plant material; psychoactive substance; designer drug; threat; health risk factor; public health; drug; adolescent

• Wydawca: -
• Czasopismo: Herba Polonica
• Rocznik: 2015
• Tom: 61
• Numer: 2
• Opis fizyczny: p.73-86,ref.

Twórcy

autor

Rondzisty A.

• Department of Humanities in Medicine, Pomeranian Medical University, Chłapowskiego 11, 70-103 Szczecin, Poland

autor

Dziekan K.

• Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Kolejowa 2, 62-064 Plewiska, Poland

autor

Kowalska A.

• Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Kolejowa 2, 62-064 Plewiska, Poland

Bibliografia

• 1. Westermeyer J. Historical and social context of psychoactive substance use disorders. In: Frances RJ, Miller SI, Mack AH (eds.). Clinical textbook of addictive disorders. 3rd ed. New york. The Guilford Press, 2005:16-34.
• 2. European Commission (2008). Eurobarometer: young people and drugs among 15–24 year olds. Analytical report. Dublin, Ireland (http://ec.europa.eu/public_opinion/flash/fl_233_en.pdf), accessed 13.06.2008.
• 3. Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res 2001; 16(4):457-469.
• 4. Wang SH, Chen WC, Lew-Ting Cy, Chen Cy, Chen WJ. Running away experience and psychoactive substance use among adolescents in Taiwan: multi-city street outreach survey. BMC Public Health 2010; 10:29. doi:10.1186/1471-2458-10-29.
• 5. Stawicka E. Nadużywanie substancji psychoaktywnych przez dzieci i młodzież. Post N Med 2006; 6:333-340.
• 6. Hibell B, Guttomrmsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A et al. Substance use among students in 36 European countries. The 2011 ESPAD Report 2012. www.espad.org/uploads/espad_reports/2011/the_2011_espad_report_full_2012_10_29.pdf.
• 7. Malczewski A, Misiurek A, Bukowska, B, Chojecki D, Jabłoński P, Kidawa M et al. National Report 2013, Poland: new developments, trends and in-depth information on selected issues. Krajowe Biuro ds. Przeciwdziałania Narkomanii.
• 8. Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu narkomanii, Dz.U. z 2005 r. Nr 179, poz. 1485.
• 9. Ustawa z dnia 20 marca 2009 r. o zmianie ustawy o przeciwdziałaniu narkomanii, Dz.U. z 2009 r. Nr 63, poz. 520.
• 10. Główny Inspektorat Sanitarny, Departament Nadzoru nad środkami Zastępczymi. Raport Głównego Inspektora Sanitarnego w sprawie środków zastępczych – trzy lata zwalczania dopalaczy w Polsce, 2013.
• 11. Malczewski A. Młodzież a substancje psychoaktywne. In: Raport CBOS – Młodzież 2013. Warszawa 2014.
• 12. Jeet K, Tomar S, Thakur N. Antipyretic activity of whole aerial part from Argyreia nervosa. Int J Pharm Pharm Sci 2012; 4 (4):76-77.
• 13. Paulke A, Kremer Ch, Wunder C , Achenbach J, Djahanschiri B, Elias A et al. Argyreia nervosa (Burm. f.): receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches. J Ethnopharmacol 2013; 148 (2):492-497.
• 14. Subramoniam A, Madhavachandran V, Ravi K, Anuja VS. Aphrodisiac property of the elephant creeper Argyreia nervosa. J Endocrinol Reprod 2007; 11(2):82-85.
• 15. Joseph A, Mathew S, Skaria BP, Sheeja EC. Medicinal uses and biological activities of Argyreia speciosa sweet (Hawaiian Baby Woodrose) – an overview. Indian J Nat Prod Res 2011; 2(3):286-291.
• 16. Padhi M, Mahapatra S, Panda J, Mishra NK. Traditional uses and phytopharmacological aspects of Argyreia nervosa. J Adv Pharm Res 2013; 4(1):23-32.
• 17. Kremer C, Paulke A., Wunder C, Toennes SW. Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds. For Sci Intern 2012; 214:e6-e8.
• 18. Bojer EW, Chao JM, Marderosian AH. Ergoline alkaloidal constituents of Hawaiian baby woodrose, Argyreia nervosa (Burm. f.). J Pharm Sc. 1973; 62:588-591.
• 19. Borsutzky M, Passie T, Paetzold W, Emrich HM, Schneider U. Hawaiian baby woodrose: (Psycho-) pharmacological effects of the seeds of Argyreia nervosa. A case-orientated demonstration. Nervenarzt 2002; 73(9):892-896.
• 20. Klinke HB, Müller IB , Steffenrud S, Dahl-SØrensen R. Two cases of lysergamide intoxication by ingestion of seeds from Hawaiian Baby Woodrose. For Sci Int 2010; 197:e1–e5.
• 21. Juszczak GR, Swiergiel AH. Recreational use of D-lysergamide from the seeds of Argyreia nervosa, Ipomoea tricolor, Ipomoea violacea, and Ipomoea purpurea in Poland. J Psych Drugs 2013; 45(1):79-93.
• 22. Sklerov J, Tevine B, Moore K.A, King T, Fowler D. Fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an Ayahuasca preparation. J Anal Toxicol 2005; 29(8):838-841.
• 23. Samoylenko V, Rahmana MM, Tekwani BL, Tripathi LM, Wang yH, Khan SI et al. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. J Ethnopharmacol 2010; 127:357-367.
• 24. Callaway JC, Glacus S, Brito MD, Neves ES. Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis. J Psychoactive Drugs 2005; 37(2):145-150.
• 25. Serrano-Dueñas M, Cardozo-Pelaez F, Sánchez-Ramos JR. Effects of Banisteriopsis caapi extract on Parkinson’s disease. Sci Rev Altern Med 2001; 5(3):139-134.
• 26. Segura-Cobos D, Venegas-Flores H, Baiza-Gutman LA, Vázquez-Cruz B. Antinociceptive and anti-Inflammatory effects of the methanol extract of Calea zacatechichi leaves and its fractions. Pharmacologyonline 2010; 2:1100-1110.
• 27. Bachliński R, Duszyńska A, Kowalczuk A, Szmajke A, Łozak A. Zastosowanie metody GC-MS do charakterystyki Calea zacatechichi i Psychotria viridis – roślin kontrolowanych ustawą o przeciwdziałaniu narkomanii. Problemy Kryminalistyki 2013; 279(1):15-21.
• 28. Rodrigues E, Carlini EA. Plants with possible psychoactive effects used by the Krahô Indians, Brazil. Rev Bras Psiquiatr 2006; 28(4):277-282.
• 29. Mayagoita L, Diaz JL, Contreas CM. Psychopharmacologic analysis of an alleged oneirogenic plant: Calea zacatechichi J Ethnopharmacol 1986; 18(3): 229-243.
• 30. Cox G, Rampes H. Adverse effects of khat: a review. Adv Psych Treat 2003; 9:456-463.
• 31. Pantelis C, Hindler CG, Taylor JC. Use and abuse of khat (Catha edulis): a review of the distribution, pharmacology, side effects and a description of psychosis attributed to khat chewing. Psychol Med 1989; 19(3):657-668.
• 32. Al-Habori M. The potential adverse effects of habitual use of Catha edulis (khat). Exp Opin Drug Saf 2005; 4(6):1129-1138.
• 33. De Felice LJ, Glennon RA, Negus S. Synthetic cathinones: Chemical phylogeny, physiology and neuropharmacology. Life Sci 2014; 97:20-26.
• 34. Wabe NT, Mohammed MA. What science says about khat (Catha edulis Forsk)? Overview of chemistry, toxicology and pharmacology. J Exp Integr Med 2012; 2(1):29-37.
• 35. Basker GV. A review on hazards of Khat chewing. Int J Pharm Pharmaceut Sci 2013; 5(3):74-77.
• 36. Lumbreras EL, Ferrer-Gallego PP, Deltoro V, Ferrando I, Ortis DG. Echinopsis pachanoi (Britton & Rose) H. Friedrich & G D. Rowley (Cactaceae) primera cita como alóctona en España. Bouteloua 2013; 16:34-35.
• 37. Kvist LP, Moraes M. Plantas psicoactivas. In: Moraes MR, Øllgaard B, Kvist LP, Borchesnius F, Balslev H. (eds.) Botánica Económica de los Andes Centrales, Universidad Mayor de San Andrés, La Paz, 2006: 294-312.
• 38. Halberstadt AL, Geyer MA. Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol 2013; 16(10):2165-2180.
• 39. Crosby DM, McLaughlin JL. Cactus Alkaloids. XIX. Crystallization of mescaline HC1 and 3-methoxytyramine HC1 from Trichocereus pachanoi. Lloydia 1973; 36(4):416-418.
• 40. O’Mahony CS. Psychoactive substances manual (ed. 1.1). South Tipparary, UK: Health Service Executive 2010.
• 41. Bienvenu E, Amabeoku GJ, Eagles PK, Scott G, Springfield EP. Anticonvulsant activity of aqueous extract of Leonotis leonurus. Phytomedicine 2002; 9:217–223.
• 42. Oyedemi SO, yakubu MT, Afolayan AJ. Antidiabetic activities of aqueous leaves extract of Leonotis leonurus in streptozotocin induced diabetic rats. J Med Plants Res 2011; 5(1):119-125.
• 43. Wua H, Lia J, Fronczeke R, Ferreiraa D. Labdane diterpenoids from Leonotis leonurus. Phytochem 2013; 91:229-235.
• 44. Jimoh FO, Adedapo AA, Afolayan AJ. Comparison of the nutritional value and biological activities of the acetone, methanol and water extracts of the leaves of Solanum nigrum and Leonotis leonorus. Food Chem Toxicol 2010; 48:964-971.
• 45. Jakubowska I, Choma J. Właściwości i oznaczanie substancji o działaniu psychoaktywnym. Biuletyn WAT 2013; 62 (2):123-143.
• 46. Popoola OK, Elbagory AM, Farouk A. Hussein A. Marrubiin. Molecules 2013; 18:9049-9060.
• 47. Souza RSO, Albuquerque UP, Monteiro JM, Amorim ELC. Jurema-Preta (Mimosa tenuiflora [Willd] Poir): a review of its traditional use, phytochemistry and pharmacology. Braz Arch Biol Technol 2008; 51:937-947
• 48. Silva VA, Gonçalves GF, Pereira MS, Gomes IF, Freitas AF, Diniz MF et al. Assessment of mutagenic, antimutagenic and genotoxicity effects of Mimosa tenuiflora. Brazil J Pharmacog 2013; 23(2):329-334.
• 49. Zippel J, Deters A, Hensel A. Arabinogalactans from Mimosa tenuiflora (Willd.) Poiret bark as active principles for wound-healing properties: specific enhancement of dermal fibroblast activity and minor influence on HaCaT keratinocytes. J Ethnopharmacol 2009; 124:391-396.
• 50. Pimentel LA, Correa FR, Gardner D, Panter KE, Dantas AF, Medeiros MRT et al. Mimosa tenuiflora as a cause of malformations in ruminants in the northeastern Brazilian semiarid rangelands. Vet Pathol 2007; 44(6):928-931.
• 51. Medeiros RM, de Figueiredo AP, Benício TM, Dantas FP, Riet-Correa F. Teratogenicity of Mimosa tenuiflora seeds to pregnant rats. Toxicon 2008; 51(2): 316-319.
• 52. Simonienko K, Waszkiewicz N, Szulc A. Roślinne środki odurzające – aktualnie obowiązująca lista w Polsce. Psychiatria Polska 2013; 47(3):499-510.
• 53. Nicasio Mdel P, Villarreal ML, Gillet F, Bensaddek L, Fliniaux MA. Variation in the accumulation levels of N,N-dimethyltryptamine in micropropagated trees and in in vitro cultures of Mimosa tenuiflora. Nat Prod Res 2005; 19(1):61-67.
• 54. Harizal SN, Mansor SM, Hasnan J, Tharakan JK, Abdullah J. Acute toxicity study of the standardarized methanolic extract of Mitragyna speciosa Korth in rodent. J Ethnopharmacol 2010; 131(2):404-409.
• 55. Kumarnsit E, Keawpradub N, Nuankaew W. Acute and long-term effects of alkaloid extract of Mitragyna speciosa on food and water intake and body weight in rats. Fitoterapia 2006; 77 (5): 339-345.
• 56. Compton DM, Garcia C, Kamaratos A, Johnson BG, Wedge T. An examination of the consequences of chronic exposure to Mitragyna speciosa during adolescence on learning and memory in adulthood. J Phytopharmacol 2014; 3(5):300-309.
• 57. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull 2004; 52(8):916-928.
• 58. Karinen R, Fosen JT, Rogde S, Vindenes V. An accidental poisoning with mitragynine. Forensic Sci Int 2014; 245:e29-e32.
• 59. Agnihotri VK, ElSohly HN, Khan SI, Smillie TJ, Khan IA, Walker LA. Antioxidant constituents of Nymphaea caerulea flowers. Phytochemistry 2008; 69(10):2061-2066.
• 60. Emboden WA. Transcultural use of narcotic water lilies in ancient Egyptian and Maya drug ritual [Abstract]. J Ethnopharmacol 1981; 3(1):39-83.
• 61. Lavanya N, Senthil Kumar KL, Karthiyayini T. Pharmacognistical studies on seeds of Nymphaea caerulea. Res J Pharm Biol Chem Sci 2011; 2(2):28-35.
• 62. Kowalczuk A, Łozak A, Fijałek ZE. Aktywność biologiczna surowców roślinnych objętych Ustawą o przeciwdziałaniu narkomanii. Przegląd Medyczny Uniwersytetu Rzeszowskiego i Narodowego Instytutu Leków w Warszawie 2012; 3:318-333.
• 63. Aslam N, Wani AA, Nawchoo IA, Bhat MA. Distribution and medicinal importance of Peganum harmala. A review. Int J Adv Res 2014; 2(2):751-755.
• 64. Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J. Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev 2013; 7(14):199-212.
• 65. Hemmateenjad B, Abbaspour A, Maghami H, Miri R, Panjehshahin MR. Partial least squares-based multivariate spectral calibration method for simultaneous determination of beta-carboline derivatives in Peganum harmala seed extracts. Anal Chim Acta 2006; 575(2):290-299.
• 66. Mohamed AHS, AL-Jammali SMJ, Naki ZJ. Effect of repeated administration of Peganum harmala alcoholic extract on the liver and kidney in Albino mice: A histo-pathological study. J Sci Innov Res 2013; 2 (3):585-597.
• 67. yuruktumen A, Karaduman S, Bengi F, Flower J. Syrian rue tea: a recipe for disaster. Clin Toxico (Phila) 2008; 46(8):749-752.
• 68. Tabudravu JN, Jaspars M. Anticancer activities of constituents of kava (Piper methysticum). South Pacific J Natur Sci 2005; 23:26-29.
• 69. Shi y, Dong JW, Zhao JH, Tang LN, Zhang JJ. Herbal insomnia medications that target GABAergic systems: a review of the psychopharmacological evidence. Curr Neuropharmacol 2014, 12(3):289-302.
• 70. Johnston E, Rogers H. Introduction. In: Johnston E, Rogers H (eds.) Hawaiian Awa: views of an ethnobotanical treasure. Hawaii. Association for Hawaiian Awa 2006:1-7.
• 71. Jackson MC. The active ingredients in ‘Awa (Kava, Piper methysticum). In: Jonston E, Rogers H (eds.) Hawaiian Awa: views of an ethnobotanical treasure. Hawaii. Association for Hawaiian Awa 2006:16-18.
• 72. Ujváry I. Psychoactive natural products: overview of recent developments. Ann Ist Super Sanita 2014; 50(1):12-27.
• 73. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 1994; 116(4):469-474.
• 74. Nowak G. Surowce roślinne o działaniu przeciwlękowym i antydepresyjnym. Herba Polonica 2009; (55)1:84-97.
• 75. Riba J, Valle M, Urbano G, yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 2003; 306(1):73-83.
• 76. Osmond H. Ololiuqui: the ancient Aztec narcotic remarks on the effects of Rivea corymbosa (Ololiuqui). J Ment Sci 1955; 101 (424):526-537.
• 77. Piekoszewski W, Florek E. Dopalacze. Przegl Lek 2009; 66(10):861-865.
• 78. Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E. New drugs of abuse. Pharmacotherapy 2015; 35(2):189-197.
• 79. Cunningham CW, Rothman RB, Prisinzano TE. Neuropharmacology of the naturally occurring κ-opioid hallucinogen salvinorin A. Pharmacol Rev 2011; 63(2):316-347.
• 80. Orton E, Liu R. Salvinorin A. A mini review of physical and chemical properties affecting its translation from research to clinical applications in humans. Transl Perioper Pain Med 2014;1(1):9-11.
• 81. Antonio T, Childers SR, Rothman RB, Dersh CM, King C, Kuehne M et al. Effect of Iboga alkaloids on μ-opioid receptor-coupled G protein activation. PLoS One 2013; 8 (10): e77262. doi:10.1371/journal.pone.0077262.
• 82. Bulling S, Schicker K, Zhang yW, Steinkellner T, Stockner T, Gruber CW et al. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem 2012; 287(22):18524-18534.

Identyfikatory

DOI

10.1515/hepo-2015-0017